- Home
- ABVC vs ALXO Comparison
ABVC vs ALXO Comparison
Compare ABVC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ALXO
- Stock Information
- Founded
- ABVC 2015
- ALXO 2015
- Country
- ABVC United States
- ALXO United States
- Employees
- ABVC N/A
- ALXO N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- ALXO Health Care
- Exchange
- ABVC Nasdaq
- ALXO Nasdaq
- Market Cap
- ABVC 22.1M
- ALXO 24.0M
- IPO Year
- ABVC N/A
- ALXO 2020
- Fundamental
- Price
- ABVC $4.20
- ALXO $0.47
- Analyst Decision
- ABVC
- ALXO Strong Buy
- Analyst Count
- ABVC 0
- ALXO 6
- Target Price
- ABVC N/A
- ALXO $3.30
- AVG Volume (30 Days)
- ABVC 571.3K
- ALXO 590.9K
- Earning Date
- ABVC 08-13-2025
- ALXO 08-07-2025
- Dividend Yield
- ABVC N/A
- ALXO N/A
- EPS Growth
- ABVC N/A
- ALXO N/A
- EPS
- ABVC N/A
- ALXO N/A
- Revenue
- ABVC $508,383.00
- ALXO N/A
- Revenue This Year
- ABVC $735.18
- ALXO N/A
- Revenue Next Year
- ABVC N/A
- ALXO N/A
- P/E Ratio
- ABVC N/A
- ALXO N/A
- Revenue Growth
- ABVC 1904.43
- ALXO N/A
- 52 Week Low
- ABVC $0.40
- ALXO $0.40
- 52 Week High
- ABVC $5.48
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- ABVC 74.35
- ALXO 48.49
- Support Level
- ABVC $2.16
- ALXO $0.44
- Resistance Level
- ABVC $5.48
- ALXO $0.47
- Average True Range (ATR)
- ABVC 0.43
- ALXO 0.03
- MACD
- ABVC 0.23
- ALXO 0.00
- Stochastic Oscillator
- ABVC 64.84
- ALXO 52.89
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.